An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
Status:
Completed
Trial end date:
2020-03-30
Target enrollment:
Participant gender:
Summary
To determine the safety of escalating IV doses of Tc 99m tilmanocept in HIV (human
immunodeficiency virus) subjects with confirmed KS and to compare results obtained from
subcutaneous and IV administrations of Tc 99m tilmanocept in the same subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Navidea Biopharmaceuticals
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)